摘要
选择高效低毒的药物及组合是提高实体瘤疗效的关键问题之一.由于肿瘤异质性、种族和个体的差异,对化疗药物的有效率及毒性各不相同.仅依赖群体研究结果数据的循证医学标准化疗难以完全指导临床实践,在药物遗传学和(或)基因组学检测指导下的"个体化化疗"被日益重视.本文以结直肠肿瘤为例,就氟尿嘧啶类药物疗效预测标志物的相关研究进展综述如下.
Selection of high-efficacy and low-toxicity drugs is key to improving the efficacy of chemotherapy for solid tumors. Because of tumor heterogeneity and ethnic/individual differences, the efficiency and toxicity of chemotherapy drugs vary across individuals. Since standard chemotherapy regi- mens developed based on population data can not completely meet clinical needs, increasing attention has been directed towards individual- ized chemotherapy based on drug genetics and/or genomics testing. In this paper, we review the advances in identifying predictive markers for response to fluoropyrirnidine-based chemotherapy for colorectal cancer.
出处
《世界华人消化杂志》
CAS
北大核心
2011年第2期170-176,共7页
World Chinese Journal of Digestology
基金
国家自然科学基金资助项目
No.30801371
上海交通大学医学院"新百人计划"基金资助项目~~
关键词
氟尿嘧啶类药物
结直肠癌
化疗效应预测
分子标志物
Fluoropyrimidine
Colorectal cancer
Prediction of response to chemotherapy
Molecular marker
作者简介
通讯作者：张俊，副主任医师，200025，上海市，上海交通大学医学院附属瑞金医院肿瘤放化疗科jun—zj@yahoo．com
